AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Contineum Therapeutics Updates Clinical Development Milestones and Reports Q2 2025 Financial Results.
ByAinvest
Tuesday, Aug 5, 2025 4:07 pm ET1min read
Contineum Therapeutics reported Q2 2025 financial results and updated key clinical development milestones. The company expects topline data from its PIPE-307 Phase 2 RRMS trial in Q4 2025, topline data from its PIPE-791 Phase 1b PET trial in Q3 2025, and initiation of its global PIPE-791 Phase 2 proof-of-concept clinical trial in IPF in Q4 2025. The company has postponed the initiation of its planned PIPE-791 PrMS and CTX-343 clinical trials and anticipates topline data from its exploratory PIPE-791 Phase 1b trial in patients with chronic pain in H1 2026.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet